Sun Pharma Advanced Research Company Ltd Share Price Today - Sun Pharma Advanced Research Company Ltd Stock Price Live NSE/BSE

Sun Pharma Advanced Research Company Ltd

NSE: SPARC BSE: 532872

₹114.89

(-4.96%)

Wed, 01 Apr 2026, 10:37 am

MTF 5xInvest in Sun Pharma Advanced Research Company Ltd with 5x Leverage Buy with MTF

Market Cap37.19B

PE Ratio0

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Sun Pharma Advanced Research Company Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
3719.02
Net Profit
-342.51
P/B
-22.16
Sector P/E
31.44
P/E
-14.03
EV/EBITDA
0
Debt/Equity (Industry)
0.57
Interest Cover (Industry)
3.73
ROCE (Industry)
6.03
RONW (Industry)
5.29
ROE
0
ROCE
0
Debt/Equity
0
EPS (TTM)
0
Dividend Yield
0
Book Value
-10.62
Interest Cover
-36.92

Analysis

all

Pros

Sun Pharma Advanced Research's cash and other short term assets cover its long term commitments.
The average tenure for the Sun Pharma Advanced Research board of directors is over 10 years, this suggests they are a seasoned and experienced board.
The average tenure for the Sun Pharma Advanced Research management team is over 5 years, this suggests they are a seasoned and experienced team.
SPARC outperformed the Market in India which returned -14.5% over the past year.
NSEI:SPARC is up 11.1% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.

Cons

Unable to evaluate Sun Pharma Advanced Research's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Sun Pharma Advanced Research's dividend against the top 25% market benchmark as the company has not reported any payouts.
Sun Pharma Advanced Research's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Sun Pharma Advanced Research has less than a year of cash runway if free cash flow continues to grow at historical rates of 32.1% each year.
Sun Pharma Advanced Research has less than a year of cash runway based on current free cash flow.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	65.67	65.67	65.67	65.67	65.67
FII	2.04	1.76	1.47	1.45	2.23
DII	0.78	1.05	0.97	1.13	0.64
Public	31.50	31.52	31.88	31.75	31.46
Government	0.00	0.00	0.00	0.00	0.00

Technical Analysis

RSI

48.65

MACD

-2.76

50 DMA

126.98

200 DMA

138.80

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	170.26	144.56	129.73	118.86	104.03	93.16	67.46
Fibonacci	144.56	134.75	128.68	118.86	109.05	102.98	93.16
Camarilla	121.96	119.60	117.25	118.86	112.53	110.18	107.82

Pivots Level: Classic

+51.40

170.26

+25.70

144.56

+10.86

129.73

118.86

Pivot Point

LTP: 120.34

-14.84

104.03

-25.70

93.16

-51.40

67.46

Moving Average

SMAEMA

Period

Value

10-EMA
118.77
20-EMA
120.52
30-EMA
122.52
50-EMA
125.55
100-EMA
130.44
200-EMA
139.94

Announcement Date	Purpose	Action	Ex Date
09 Feb 2026	board-meetings	Quarterly Results
16 Jan 2026	egm
10 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
08 Jul 2025	agm
08 Jul 2024	agm
12 Jul 2023	agm
26 Aug 2022	agm
03 Sept 2021	agm
21 Aug 2021	agm	Annual General Meeting	23 Sept 2021
12 May 2021	egm

Sun Pharma Advanced Research Company Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd

Lupin Ltd

Sun Pharma Advanced Research Company Ltd About

Sun Pharma Advanced Research Company is engaged in the business of research and development (R&D) of pharmaceutical products.

Industry

Miscellaneous

Founded

2006

Headquarters

CEO

Dilip S Shanghvi

Employees

Contact

Website

http://www.sparc.life

secretarial@sparcmail.com

Phone

91-265-2330815/2339257

Location

Sun Pharma Advanced Res Centre, Akota Road Akota, Vadodara, Gujarat, 390020

Year	History
2019	SPARC entered into a licensing agreement with Bioprojet to acquire exclusive rights for investigational medicinal product, SCD-044. SPARC entered into a licensing agreement with Bioprojet to acquire exclusive rights for investigational medicinal product. HitGen and SPARC entered into a DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration. SPARC received Orphan Drug Designation from the USFDA for SCO-088 for the treatment of patients with Chronic Myeloid Leukemia. SPARC entered into a licensing deal with CMS.
2020	Sun Pharma Advanced Research Company Ltd granted an exclusive license to Tripoint Therapeutics LLC to commercialize ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg tablets in the USA. Sun Pharma Advanced Research Company Ltd got positive top-line results from its Phase 3 trial for its investigational drug, SDN-037, for the treatment of Inflammation and Pain associated with Ocular Surgery. SPARC provided an update on Clinical Programs and R&D Pipeline.
2021	SPARC entered into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target. Sun Pharma Advanced Research Company Ltd granted exclusive worldwide rights to Visiox Pharma LLC for the development and commercialization of PDP-716 and SDN-037.
2022	Sun Pharma and SPARC entered into a license agreement for commercialization of phenobarbital for injection in the US.
2023	Sun Pharma Advanced Research Company Ltd entered into a licensing agreement to acquire exclusive rights for SCD-153. Sun Pharma Advanced Research Company Ltd formed a US subsidiary.

Client Name	Order Side	QTY	Avg Price	Date
NK SECURITIES RESEARCH PRIVATE LIMITED	Sell	1940152	153.84	04 Dec 2025
IRAGE BROKING SERVICES LLP	Sell	1912360	154.79	04 Dec 2025
IRAGE BROKING SERVICES LLP	Buy	2131080	154.58	04 Dec 2025
NK SECURITIES RESEARCH PRIVATE LIMITED	Buy	1940152	153.76	04 Dec 2025
ALPHAGREP SECURITIES PRIVATE LIMITED	Sell	2898504	153.34	04 Dec 2025
IRAGE BROKING SERVICES LLP	Sell	1376746	152.73	04 Dec 2025
IRAGE BROKING SERVICES LLP	Buy	1151539	152.44	04 Dec 2025
ALPHAGREP SECURITIES PRIVATE LIMITED	Buy	2898504	153.27	04 Dec 2025
ALPHAGREP SECURITIES PRIVATE LIMITED	Buy	3962735	167.44	03 Dec 2025
IRAGE BROKING SERVICES LLP	Buy	2090002	166.63	03 Dec 2025

Sun Pharma Advanced Research Company Ltd News

Sun Pharma Advanced Research Clarifies Volume Surge

Sun Pharma Advanced Research Company confirms compliance with SEBI disclosure regulations following BSE inquiry about increased trading volume on March 27, 2026.

27 Mar 2026

companies

SPARC Files Addendum to Valuation Report Post NSE Query

Sun Pharma Advanced Research Company submits addendum to valuation report following NSE clarifications, explaining why DCF method wasn't used for clinical-stage biopharmaceutical company valuation.

24 Feb 2026

stocks

SPARC Reports Q3 FY26 Loss of ₹80.57 Crores

Sun Pharma Advanced Research Company posted a net loss of ₹80.57 crores in Q3 FY26 with revenue declining to ₹8.45 crores. Company recognized exceptional costs of ₹12.36 crores related to new labour codes.

09 Feb 2026

co actions results

SPARC Receives FDA Priority Review Voucher for Sezaby®

Sun Pharma Advanced Research Company announces receipt of Priority Review Voucher from FDA associated with Sezaby® approval, providing strategic flexibility to accelerate pipeline development.

03 Feb 2026

stocks

SPARC Issues Corrigendum to EGM Notice for Feb 9 Meet

Sun Pharma Advanced Research Company issues corrigendum to EGM notice dated January 14, 2026, addressing NSE observations and providing additional clarity on shareholding pattern.

29 Jan 2026

stocks

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800